KIMBERLY STANLEY: Open Payments
NPI 1770824955 · MANTACHIE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$430 in 23 payments from 10 companies in 2025. Trend: 2023 $106 · 2024 $30 · 2025 $430
Food & beverage: $430
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $98 |
| Sequel Med Tech, LLC | 4 | $80 |
| Corcept Therapeutics | 4 | $77 |
| Lilly USA, LLC | 3 | $49 |
| Novo Nordisk Inc | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Amgen Inc. | 1 | $24 |
| CeQur Corporation | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: TWIIST, Korlym, FARXIGA, MOUNJARO, JARDIANCE, NEXLETOL, EVENITY, CeQur Simplicity.
Industry payments across MS — which companies pay providers there.
